Meeting
2023 ASCO Annual Meeting
Neoadjuvant durvalumab and tremelimumab in resectable locally advanced SCC of the oral cavity: DUTRELASCO study.
Authors
Michel Bila
University Hospitals Leuven - Catholic University Leuven, Leuven, Belgium
Michel Bila , Amelie Franken , Jeroen Van Dessel , Sara Verbandt , Valentina Pomella , Sigrid Hatse , Thomas Van Brussel , Rogier Schepers , Cedric Van Aerde , Karolien Goffin , Vincent Vandecaveye , Esther Hauben , Vincent Vander Poorten , Sabine Tejpar , Diether Lambrechts , Paul M. Clement
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03784066
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6081)
DOI
10.1200/JCO.2023.41.16_suppl.6081
Abstract #
6081
Poster Bd #
73
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Neoadjuvant durvalumab +/- tremelimumab affects the expression of immune checkpoint (IC) molecules on myeloid derived suppressor cells (MDSC) in patients (pts) with locally advanced renal cell carcinoma (RCC).
First Author: Jaleh Fallah
Poster
2023 ASCO Annual Meeting
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
First Author: Robert L. Ferris
Poster
2022 ASCO Annual Meeting
Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial.
First Author: Markus Hecht
Poster
2020 ASCO Virtual Scientific Program
A phase Ib trial of neoadjuvant/adjuvant durvalumab +/- tremelimumab in locally advanced renal cell carcinoma (RCC).
First Author: Moshe Chaim Ornstein